Dr. Cropsey is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Oklahoma Health Campus and Associate Dean for Clinical Research in the College of Medicine. A licensed clinical psychologist, Cropsey has more than 25 years of experience conducting clinical research focused on substance use disorders, including nicotine, alcohol, and opioid use.
Her research focuses on developing and evaluating accessible, evidence-based interventions to prevent and treat substance use and related health risks. Current research includes remotely delivered interventions for alcohol and tobacco use, opioid overdose prevention, fentanyl test strip education, and sleep and circadian factors among people receiving opioid maintenance treatment. Cropsey's work incorporates innovative approaches such as telehealth, social media recruitment, and digital health technologies to reach underserved populations.
Over the course of their career, Dr. Cropsey has served as principal or multiple principal investigator on more than $20 million in NIH-funded research. Her work has included studies addressing tobacco treatment among people with HIV and individuals involved in the criminal legal system, opioid use disorder, alcohol use, and behavioral health interventions. In 2019, Dr. Cropsey provided expert testimony to the U.S. Senate Committee on Appropriations on the opioid overdose epidemic.
Before joining the University of Oklahoma, Dr. Cropsey served as Vice Chair for Clinical Research in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham and directed the UAB Center for Addiction and Pain Prevention and Intervention (CAPPI).
Education:
Degree-Granting Institutions
M.S. Virginia Commonwealth University, Richmond, Virginia
Specialization: Biostatistics
Psy.D. Indiana State University, Terre Haute, Indiana
Specialization: Clinical Psychology
Internship Virginia Commonwealth University, Richmond, Virginia
Specialization: Clinical Psychology (APA-accredited)
M.S. University of Wisconsin-Madison, Madison, Wisconsin
Specialization: Education Psychology
B.S. University of Wisconsin-Madison, Madison, Wisconsin
Major: Psychology
Postgraduate Training
Post-doc Virginia Commonwealth University, Richmond, Virginia, October 2002
Specialization: Addiction
Post-doc University of Mississippi Medical Center, Jackson,
Mississippi, April 2000
Specialization: Forensic Psychology
Clinical/Research Interests:
My research interests have focused on clinical trial interventions for substance use disorders among underserved populations such as individuals in the criminal legal system and persons living with HIV/AIDS. I have conducted several clinical trials of smoking cessation interventions as well as clinical trials for opioid use disorders and alcohol use disorders in criminal legal and HIV treatment settings, respectively. More recently, I have been studying the interface of sleep and circadian problems with substance use disorders.
Funding:
1UG3TR004797-01A1; MPI: Hawk, Mahoney
NCATS/NIH $2,136,696
Improving Efficiency, Quality, and Equity: Randomized Controlled Evaluations of Remote vs. In-Person Clinical Trial Methods
This project will compare in person to remote methods in clinical trials research among three different behavioral/pharmacotherapy clinical trials: 1) smoking cessation with NRT; 2) use of a depression app; 3) naloxone training and kit to prevent overdose.This project will determine if in person methods can provide similar or superior recruitment, retention and intervention delivery rigor as traditional in person clinical trials.
Role: Site PI
R01DA059471; MPI: Cropsey, Gamble
09/30/23-08/31/27
NIH/NIDA $4,402,639
Medications for opioid use disorder differentially modulate intrinsically photosensitive retinal ganglion cell function, sleep, and circadian rhythms: implications for treatment
In this project we will explore how opioids cause sleep disturbance and circadian misalignment among intrinsically photosensitive retinal ganglion cells (ipRGCs) in the retina of the eye among persons maintained on medications for opioid use disorder.
1R61DA065247-01; MPI: Kay, Cropsey
04/01/26-03/31/28
NIH/NIDA $447,000
A Remote Intervention to Prevent Overdose among People who Use Stimulants and/or Opioids
This Type 1 hybrid effectiveness-implementation randomized controlled trial, A Remote Intervention to Prevent Overdose among People who Use Stimulants and/or Opioids, aims to address the United States overdose crisis driven by fentanyl and other synthetic opioids by reducing overdose rates. This study will be the first national, fully remote trial to isolate the independent impact of overdose prevention education on overdose outcomes. Findings will directly inform scalable, low-barrier models capable of reaching rural and underserved populations not currently engaged in substance use services.
Select Honors and Accomplishments:
UAB Heersink School of Medicine Dean’s Award for Excellence in Mentoring (senior), University of Alabama at Birmingham (June 2021)
Graduate Dean’s Award for Excellence in Mentoring, University of Alabama at Birmingham (March 2013)
SRNT Service Award, presented at the 2012 SRNT conference for service as the SRNT Newsletter Editor from 2007-2012 (February 2012)
John McCain Fellowship Award, presented for the prize-winning paper, South Atlantic Association of Obstetricians and Gynecologists (January 2009)
National Institute on Drug Abuse, Young Investigator Award, presentedfor prize-winning poster, American Psychological Association (August 2005)
American Association of Medical Colleges Early Career Women Faculty Professional Development Seminar (December 2004)
NIH Loan Repayment for Clinical Research (September 2003)
College on Problems of Drug Dependence (CPDD) Early Career Investigator Travel Award (June 2002)
Indiana State University Research Award (March 1998)